Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss

Key Takeaways Amarin reported Q4 adjusted EPS of 1 cent, beating estimates despite a 21% revenue decline.AMRN's Vascepa sales fell 23% year over year, hit by lower U.S. prices and Europe's Recordati shift.Amarin achieved positive Q4 cash flow and targets $70M in annual cost savings.Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of a loss of $1.27. The company had reported an adjusted loss of 2 cents per share in t ...